https saf.wellsfargoadvisors.com emx dctm research asg dsip dsip_stocks.pdf Concept Review Rolling Performance Results - DSIP
Description
At the 12 mg dose, 93% of participants achieved at least 5% weight loss
December 21, 2024
Phase 2 dominates growth : Phase 2 trials jumped significantly from 1,711 (2024) to 2,278 (2025), the highest level ever seenmaking Phase 2 the primary growth engine
Furthermore, there was no lethality and BPC-157 appeared to work in a different manner from existing medications known to cause numerous side effects
